Genentech appoints new CEO
Genentech, a member of the Roche Group, has named Alexander Hardy CEO effective March 1.
Hardy first joined Genentech in 2005, where he held several senior management positions, including leading patient access services and overseeing commercial operations for a range of therapeutic areas from HER2-positive cancer to influenza and neuroscience.
In 2014, he became head of Asia Pacific for Roche Pharmaceuticals, and is currently head of global product strategy. Hardy succeeds Bill Anderson, who was recently appointed CEO of Roche.
“We’re delighted to welcome Alexander back to Genentech as chief executive officer,” Anderson said. “He brings significant global expertise in the delivery of breakthrough medicines and a deep connection to the company culture. I look forward to seeing Genentech’s scientific excellence, employee experience and dedication to patients thrive under his leadership.”
Hardy first joined Genentech in 2005, where he held several senior management positions, including leading patient access services and overseeing commercial operations for a range of therapeutic areas from HER2-positive cancer to influenza and neuroscience.
In 2014, he became head of Asia Pacific for Roche Pharmaceuticals, and is currently head of global product strategy. Hardy succeeds Bill Anderson, who was recently appointed CEO of Roche.
“We’re delighted to welcome Alexander back to Genentech as chief executive officer,” Anderson said. “He brings significant global expertise in the delivery of breakthrough medicines and a deep connection to the company culture. I look forward to seeing Genentech’s scientific excellence, employee experience and dedication to patients thrive under his leadership.”